Beth Caldwell: People like me will die because of these cuts

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Beth Caldwell, a patient with metastatic neuroendocrine breast cancer, has more to lose than anyone else in the controversy over President Donald Trump’s proposed cuts to the NIH budget.

Caldwell, who is undergoing treatment at the Fred Hutchinson Cancer Center, spoke at a news conference broadcast live on the cancer center’s Facebook page.

The text of her remarks follows:

My name is Beth Caldwell and I have metastatic neuroendocrine breast cancer. I was diagnosed in March of 2014. I found a lump in my breast and I was 37, too young to be getting mammograms yet, and it turned out that it had already spread to my bones, which means that it’s incurable, currently. And I’d like to add that currently, the more research we do, the more likely it is that I’m going to live to see my children into adulthood.

My children right now are five and nine. My goal when I was initially diagnosed was to see my youngest start kindergarten, and she will in the fall. I would really like to set some new goals, but it’s hard to do that when we see research funding cuts happening.

I’ve lost—I can’t even tell you—how many friends with metastatic cancers within the time since I’ve been diagnosed. I lost one this week. Another friend told me today she was just diagnosed with brain metastases, which means that her expected life span just shortened by quite a bit. And it’s not okay. It’s just not acceptable that people will die because of these cuts.

And I’m going to say that again—people like me will die because of these cuts. We just spent all this effort getting the 21st Century Cures Act passed, which slated more funding for research, including into cancer. And to see that undone, I feel like our government will have blood on its hands if these cuts go through. I frankly would love to watch my children grow into adulthood but I think currently, that’s not likely to happen.

The only treatments left for me are going to be ones that are experimental. I’ve been through all the regular treatments already in the past three years and they’ve all stopped working, which is what happens when you have metastatic cancer. You take a drug until it stops and then you take a new one. And if there aren’t new ones, then you die.

So we need this funding for NIH. We need funding for research to keep patients alive longer, to keep them alive longer with a quality of life that’s acceptable. And so I desperately hope that people will begin to contact their members of Congress and demand that this budget with these cuts to NIH not be passed.

Table of Contents

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login